Eli Lilly announced results from a “first-of-its-kind study” of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented at the American Academy of Dermatology Annual Meeting. The lebrikizumab efficacy results from this trial are consistent with data in other Phase 3 studies, which further reinforces lebrikizumab’s potential to be a first-line biologic treatment following topical prescription therapies for people across a range of skin tones with moderate-to-severe atopic dermatitis. The initial 16-week data from this study evaluated 50 patients with moderate-to-severe atopic dermatitis and darker skin tones as measured by the Fitzpatrick scale, including people who self-identify as Black or African American, Asian, American Indian or Alaska Native. Of the 50 patients, 11 also self-identified as Hispanic/Latinx with the remaining 39 self-identifying as non-Hispanic/Latinx. All patients received lebrikizumab 500-mg subcutaneously initially and at two weeks followed by 250-mg subcutaneously every two weeks to Week 16. Results at 16 weeks were consistent with the 16-week results from the ADhere and ADvocate 1 & 2 studies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Slips after Surprise FDA Snub
- Eli Lilly falls $3.16 to $777 after FDA delays decision on Alzheimer’s drug
- Eli Lilly reports FDA to convene PCNS meeting to discuss TRAILBLAZER-ALZ 2 trial
- Viking Therapeutics initiated with a Buy at Jefferies
- Eli Lilly & Co. (NYSE:LLY) Slips on Soaring Demand News